Kaneko Hidehiro*
Checkpoint inhibitors have revolutionized the field of oncology by harnessing the power of the immune system to combat cancer. These agents, such as Programmed Cell death Protein 1 (PD-1) and Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA-4) inhibitors, work by blocking inhibitory signals that cancer cells exploit to evade immune recognition and destruction. This article provides an in-depth exploration of checkpoint inhibitors, their mechanisms of action, clinical applications, and current challenges in the field.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 